Lee James O'Callaghan – Trademark Portfolio

Entity Type: 01

Lee James O'Callaghan holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include HB5. The owner is based in Squamish, BC.

1008 Pine Drive

Squamish, BC V8B0W9 , CA

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

HB5
HB5
Registered 2022

Trademark Classifications

Lee James O'Callaghan's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

41
Education & Entertainment (1 filing)

Education; providing of training; entertainment; sporting and cultural activities

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Lee James O'Callaghan have?

Lee James O'Callaghan has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does Lee James O'Callaghan file in?

Lee James O'Callaghan files trademarks across 2 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 5 (Pharmaceuticals). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.

What are Lee James O'Callaghan's most well-known trademarks?

Lee James O'Callaghan's registered trademark portfolio includes well-known marks such as HB5. These are among 1 currently registered trademark in the portfolio.

What is Lee James O'Callaghan's trademark registration success rate?

Lee James O'Callaghan has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.